¹û¶³ÊÓƵ

Pioneering the next generation of mental health treatments
We are on a mission to develop effective, rapid-acting and accessible medicines for people living with mental health conditions
About Us
Self Reflected by Greg Dunn
Reducing
the unmet
need in
mental
health
Nearly 1 billion people suffer from mental disorders around the world.
The global economic cost of mental health disorders is expected to reach $6 trillion by 2030.
Most people living with a mental disorder do not have access to effective care.

We want to be a part of the solution. 


Leveraging
the potential of
next-generation
compounds

Studies have shown that our investigational psychedelic-based compounds

can be administered in a short clinic visit
are well-tolerated
can deliver rapid, robust, and lasting treatment effects
More about
Our Pipeline
Therapeutic Focus
Clinical Trials
Supporting
patients
and
trial
participants

We are proud to support initiatives in-house and across the mental health landscape to accelerate research into novel mental health treatments and enhance the patient experience.

More about
Patients
News
and
views
July 1, 2025

atai Life Sciences and ¹û¶³ÊÓƵ Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose
… Read more
June 12, 2025

Results from ¹û¶³ÊÓƵ’s Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) for Alcohol Use Disorder to be presented at CPDD 2025

¹û¶³ÊÓƵ Ltd today announces that clinical and micro-phenomenology data from its Phase IIa study of BPL-003 for AUD will be presented at the 87th Annual Scientific Meeting of the US College on Problems of Drug Dependence (CPDD) from 14 - 18 June 2025 in New Orleans.
… Read more
June 2, 2025

atai Life Sciences and ¹û¶³ÊÓƵ to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic
… Read more
Read all news